Shares of Cellebrite DI Ltd. (CLBT) Have Risen Above Previous 52-Week High

April 12, 2022 11:06:25

Cellebrite DI Ltd. (NASDAQ:CLBT) traded at a new 52-week high today of $15.14. This new high was reached on above average trading volume as 2.6 million shares traded hands, while the average 30-day volume is approximately 289,000 shares.

In the past 52 weeks, Cellebrite DI Ltd. share prices are bracketed by a low of $5.07 and a high of $15.14 and is now at $5.93, 17% above that low price.

Cellebrite DI Ltd. (NASDAQ:CLBT) is currently priced 0.6% above its average consensus analyst price target of $5.90.

Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer